Abstract: Method and apparatus for configuring systems implementing diverse platforms in a network is described. In one example, functional units of the systems are exposed to define abstract function signatures. A template is specified using at least one of the abstract function signatures to define at least one executable task. The template is translated into configuration data adapted to configure each of the system to collectively perform the at least one executable task. The configuration data is applied to the systems through a coupler layer adapted to interface with each of the diverse platforms.

Abstract: Devices, systems and methods are disclosed which enable a user of a communications device to receive a notification of a priority and a context of a call before answering the call. A caller records a short phrase to be played on the callee's device either in place of ringing or following a predetermined amount of rings controlled by the callee's preferences. Among the callee's preferences is a selection of priority, such as among low, high, and critical. When callee's communications device is in any of these modes, every incoming call is intercepted giving the caller the opportunity to provide a short phrase for the context of the call and choose a priority level. This short phrase is played on the callee's communications device if the specified priority of the call matches or exceeds the current mode set on the callee's communications device, and the callee may answer.

Abstract: Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

Abstract: A platform for the automated testing of event driven software applications is provided. A source environment is replicated to a target environment. The target environment includes a target system. A test case is defined with a target system, specific attributes and verification information. The attributes of the test case include the target system. The test case is fired. An event is simulated for the test case based on the target system and the specific attributes. The simulated event is transmitted to the target environment. The results of the test case being fired are determined based on verification information. The results are recorded to a data store.

Abstract: A platform for the automated testing of event driven software applications is provided. A source environment is replicated to a target environment. The target environment includes a target system. A test case is defined with a target system, specific attributes and verification information. The attributes of the test case include the target system. The test case is fired. An event is simulated for the test case based on the target system and the specific attributes. The simulated event is transmitted to the target environment. The results of the test case being fired are determined based on verification information. The results are recorded to a data store.

Abstract: Devices, systems and methods are disclosed which enable a user of a communications device to receive a notification of a priority and a context of a call before answering the call. A caller records a short phrase to be played on the callee's device either in place of ringing or following a predetermined amount of rings controlled by the callee's preferences. Among the callee's preferences is a selection of priority, such as among low, high, and critical. When callee's communications device is in any of these modes, every incoming call is intercepted giving the caller the opportunity to provide a short phrase for the context of the call and choose a priority level. This short phrase is played on the callee's communications device if the specified priority of the call matches or exceeds the current mode set on the callee's communications device, and the callee may answer.

Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.